From the group of IL-17 inhibitors, Ixekizumab was the first IL-17A antagonist approved in 2020 for the treatment of pediatric patients with moderate to severe plaque psoriasis [41,42,43]. This evidence concerns the gene IL17A and psoriasis vulgaris.